TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3662908
Drug: Topical epinephrine
Normalized name: epinephrine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical epinephrine (1.25%)
Study: 27562221
Drug: Access therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access therapy with PRF + 1% ALN
Study: 27562221
Drug: Access therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access therapy with PRF
Study: 27562221
Drug: Access therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access therapy alone
Study: 25635577
Drug: Ocriplasmin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin (125 µg)
Study: 18356546
Drug: tPA +
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA + TCD + 2.8 mL microS (Target)
Study: 17201276
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy of cardiac insufficiency
Study: 15268733
Drug: Sirolimus (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (4-8 ng/mL) plus Tacrolimus (8-12 ng/mL for 3 months, then 5-10 ng/mL)
Study: 15268733
Drug: Sirolimus (8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (8-16 ng/mL) plus Tacrolimus (3-8 ng/mL, with tacrolimus elimination from month 3)
Study: 15268733
Drug: Sirolimus (8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (8-16 ng/mL) plus Tacrolimus (3-8 ng/mL, with tacrolimus elimination from month 3) after protocol amendment
Study: 11194595
Drug: Short bursts
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short bursts (5 s) without treatment (group A)
Study: 11194595
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of propafenone 600 mg with short bursts (group B)
Study: 11194595
Drug: Prolonged bursts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged bursts (30 s) without treatment (group C)
Study: 11194595
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of propafenone 600 mg with prolonged bursts (group D)
Study: 3933287
Drug: HCFU (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCFU (600 mg/day)
Study: 3933287
Drug: Tegafur (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur (800 mg/day)
Study: 3933287
Drug: HCFU (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCFU (in patients taking drugs for more than 90 days)
Study: 3933287
Drug: Tegafur (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur (in patients taking drugs for more than 90 days)
Study: 31867637
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Nicotine Cigarettes (VLNC; 0.4 mg nicotine/g tobacco)
Study: 22471127
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy with Xiongbai Qianlie powder
Study: 20702745
Drug: Twice-weekly MMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly MMN
Study: 20702745
Drug: Once-weekly MMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly MMN
Study: 20702745
Drug: Twice-weekly IFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly IFA
Study: 11534421
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) administered in continuous intravenous infusion
Study: 11534421
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - sodic dalteparine with dicumarinic afterwards
Study: 9342997
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of medications
Study: 27592828
Drug: β‐CRX-rich orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐CRX-rich orange juice (125 mL, once a day, after breakfast)
Study: 27592828
Drug: Placebo (β‐CRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (β‐CRX removed from orange juice, 125 mL, once a day, after breakfast)
Study: 24118703
Drug: Response-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-guided therapy (RGT) with boceprevir plus peginterferon alfa-2b and ribavirin (BOC/PR)
Study: 24118703
Drug: Response-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-guided therapy (RGT)
Study: 22085697
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg pregabalin + 10 mg oxycodone
Study: 18275008
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once weekly (n=21)
Study: 18275008
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 microg once daily (n=23)
Study: 12064847
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - 6 sessions
Study: 17050503
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lisinopril
Study: 6458919
Drug: Theophylline capsules
Normalized name: Theophylline Capsules
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline capsules
Study: 6436931
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg intravenously
Study: 6436931
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA), indomethacin, noramidopyrine intravenously, and acetaminophen orally during a bronchospastic attack
Study: 25041619
Drug: Allogeneic living
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic living cell bioformulation with compression therapy
Study: 22943926
Drug: Single-dose delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose delivery system (SDS)
Study: 22943926
Drug: Multi-dose delivery
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose delivery system (MDS)
Study: 22943926
Drug: Single-dose delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose delivery system (SDS) and Multi-dose delivery system (MDS)
Study: 20934572
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid 135 mg + Atorvastatin 40 mg + Ezetimibe 10 mg (FA + Atorva/Eze)
Study: 20934572
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg + Ezetimibe 10 mg (Atorva/Eze)
Study: 17002609
Drug: Clinical response
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical response during the first days of treatment
Study: 3900796
Drug: Milenperone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milenperone (2 X 10 mg daily for 6 weeks)
Study: 8772689
Drug: Plasma norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma norepinephrine (PNE) levels above the median of 393 pg/mL
Study: 6419264
Drug: 3-cyano-imipramine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-cyano-imipramine (1 mg rising to 3 mg daily for 7 days)
Study: 29107059
Drug: PHARMA (optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHARMA (optimized pharmacological treatment)
Study: 23283758
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at a dosage of .3 mg/kg
Study: 12806341
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide bleaching agent, bonded immediately (Group B)
Study: 12806341
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide bleaching agent, stored in artificial saliva for 30 days before bonding (Group C)
Study: 10827367
Drug: TEE‐guided subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEE‐guided subcutaneous enoxaparin bridge therapy
Study: 10827367
Drug: TEE‐guided intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEE‐guided intravenous unfractionated heparin bridge therapy
Study: 1513578
Drug: Heparin surface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin surface modified IOL
Study: 26531095
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 supplementation (1800 mg per day)
Study: 25294055
Drug: SaiLuoTong 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: SaiLuoTong 360 mg per day for 52 weeks
Study: 25294055
Drug: SaiLuoTong 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: SaiLuoTong 240 mg per day for 52 weeks
Study: 25294055
Drug: SaiLuoTong 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: SaiLuoTong 360 mg per day during the extension phase
Study: 25294055
Drug: SaiLuoTong 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: SaiLuoTong 240 mg per day during the extension phase
Study: 19653976
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (7.5 g daily for 12 weeks)
Study: 19653976
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (7.5 g daily for 12 weeks)
Study: 19653976
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (7.5 g daily during open-label phase)
Study: 19653976
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (7.5 g daily during open-label phase)
Study: 17761977
Drug: CI-1033 50
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-1033 50 mg daily for 21 consecutive days
Study: 17761977
Drug: CI-1033 150
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-1033 150 mg daily for 21 consecutive days
Study: 17761977
Drug: CI-1033 450
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-1033 450 mg daily for 14 consecutive days followed by 7 days of no treatment
Study: 15549466
Drug: 1% ropivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ropivacaine, 12 ml
Study: 15549466
Drug: 2% mepivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mepivacaine, 18 ml
Study: 8836468
Drug: Yohimbine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (in combination with other drugs)
Study: 8836468
Drug: Other medications
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medications containing yohimbine
Study: 8836468
Drug: Yohimbine plus
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine plus other drugs (uncontrolled trials)
Study: 2271802
Drug: Group behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group behavioral medicine interventions (two types)
Study: 492047
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml Trental (= 200 mg pentoxifylline)
Study: 492047
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (= placebo)
Study: 27054321
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea supplementation (0.56 g/d epigallocatechin-gallate + 0.28 ∼ 0.45 g/d caffeine)
Study: 1555981
Drug: Pre- or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- or postoperative radiation therapy (45 Gy/5 weeks)
Study: 29068050
Drug: Nose blowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nose blowing at least twice daily for the first 7 postoperative days
Study: 26980614
Drug: iTBS administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: iTBS administered over ipsilesional primary motor cortex (M1-stimulation group)
Study: 25325205
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day bupropion
Study: 22301476
Drug: CCIV (cell-culture-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCIV (cell-culture-derived influenza vaccine)
Study: 22301476
Drug: TIV (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV (conventional egg-derived trivalent influenza vaccine)
Study: 20406241
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg (up-titrated to 300 mg)
Study: 20406241
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg (up-titrated to 10 mg)
Study: 17623606
Drug: Intra-articular analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular analgesic mixture (adrenaline, morphine, bupivacaine) administered during ACL reconstruction (groups 3 and 4)
Study: 17623606
Drug: Intra-articular analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular analgesic mixture (adrenaline, morphine, bupivacaine)
Study: 17623606
Drug: No intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intra-articular analgesic (groups 1, 2, and 5)
Study: 12392805
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly cognitive behavioral therapy sessions
Study: 12392805
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly cognitive behavioral therapy sessions
Study: 12392805
Drug: Biweekly cognitive
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly cognitive behavioral therapy sessions
Study: 10580197
Drug: Canarypox virus
Normalized name: Canarypox virus Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canarypox virus vaccine (vCP300)
Study: 10580197
Drug: Control injections
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injections
Study: 2206824
Drug: Ciba-Geigy carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciba-Geigy carbamazepine preparation
Study: 2206824
Drug: Ethical Generics
Normalized name: Genesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethical Generics carbamazepine preparation
Study: 29781243
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements containing Bifidobacterium and Lactobacillus
Study: 28544702
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in high-fat dairy and cream intake
Study: 21130513
Drug: DPP-IV inhibitor
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP-IV inhibitor PF-734200 (multiple doses for 28 days)
Study: 19608530
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg once daily and Aspirin 350 mg twice daily
Study: 17553909
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) plus non-steroidal anti-inflammatory drugs (NSAIDs)
Study: 8165192
Drug: Sandimmune Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune Neoral (microemulsion formulation)
Study: 8165192
Drug: Sandimmune (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune (commercial formulation)
Study: 31297890
Drug: Breastfed infants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breastfed infants given formula supplements
Study: 25299350
Drug: Extended-release tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tramadol HCl 75 mg/acetaminophen 650 mg (TA-ER)
Study: 25299350
Drug: Immediate-release tramadol
Normalized name: tramadol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tramadol HCl 37.5 mg/acetaminophen 325 mg (TA-IR)
Study: 15979735
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg i.v. dexamethasone preoperatively
Study: 8727868
Drug: Felodipine (Plendil)
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine (Plendil) 10 mg
Study: 28418835
Drug: DT2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DT2 treatment
Study: 28418835
Drug: CMP4 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMP4 treatment
Study: 25377788
Drug: Percentage dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage dose protocol (group 1)
Study: 25377788
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose protocol (group 2)
Study: 20051190
Drug: Elapsed time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elapsed time to first bowel movement from initiation of bowel preparation
Study: 20051190
Drug: Adequate bowel
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate bowel preparation
Study: 11383595
Drug: Infliximab (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5, 10, or 20 mg/kg body weight)
Study: 9923056
Drug: Intranasal levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal levocabastine
Study: 4456575
Drug: Small doses
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small doses of heparin
Study: 28202475
Drug: Carbohydrate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (50 g) added to standard white-bread challenge
Study: 28202475
Drug: Protein (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein (50 g) added to standard white-bread challenge
Study: 28202475
Drug: Fat (11.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat (11.1 g) added to standard white-bread challenge
Study: 28202475
Drug: Fiber (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber (4.8 or 9.6 g) added to standard white-bread challenge
Study: 26415035
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplementation (1 mg/kg/day) for six months
Study: 17426747
Drug: Glucose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (25 or 50 g portions)
Study: 16402242
Drug: Rabeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (40 mg)
Study: 10715293
Drug: Sucralfate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1.5 g orally every 6 hours)
Study: 1586618
Drug: CHOP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, doxorubicin 50 mg/m2, prednisone 50 mg/m2)
Study: 1586618
Drug: CNOP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNOP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, mitoxantrone 10 mg/m2, prednisone 50 mg/m2)
Study: 31704907
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine combining EGFR-TKI (n=92)
Study: 31704907
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine combining EGFR-TKI for 19DEL mutant NSCLC
Study: 31704907
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine combining EGFR-TKI for L858 mutant NSCLC
Study: 31704907
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine combining EGFR-TKI
Study: 24669010
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC)
Study: 17288699
Drug: Clarithromycin immediate-release
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin immediate-release (IR) 500 mg twice daily for 7 days or telithromycin 800 mg once daily for 5 days (comparator)
Study: 12494803
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (n = 22), 10 mg/h during 2 h then 5 mg every 4 h
Study: 12494803
Drug: Nebulized adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized adrenaline (n = 22), 6 mg/h during 2 h then 3 mg every 4 h
Study: 2920500
Drug: Phenylpropanolamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine infusion (0.44 mg/kg)
Study: 1082383
Drug: TNM1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNM1 vaccine
Study: 30958062
Drug: Caffeinated chewing
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated chewing gum (300 mg of caffeine)
Study: 25545858
Drug: Varenicline (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (dose increased to a maximum of 5 mg/d)
Study: 19099294
Drug: Cannabis cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis cigarettes containing 0 mg THC (placebo)
Study: 19099294
Drug: Cannabis cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis cigarettes containing 29.3 mg THC
Study: 19099294
Drug: Cannabis cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis cigarettes containing 49.1 mg THC